ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Everest Medicines Ltd. ?
1
Weak Long Term Fundamental Strength with a 13.72% CAGR growth in Operating Profits over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -217.30
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -49.87%, its profits have risen by 103.5% ; the PEG ratio of the company is 3.2
3
Underperformed the market in the last 1 year
- Even though the market (Hang Seng Hong Kong) generated negative returns of -4.77% in the last 1 year, its fall in the stock was much higher with a return of -49.87%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Everest Medicines Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Everest Medicines Ltd.
-49.2%
0.50
75.85%
Hang Seng Hong Kong
-4.77%
-0.26
18.70%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
556.73%
EBIT Growth (5y)
13.72%
EBIT to Interest (avg)
-42.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.26
Sales to Capital Employed (avg)
0.10
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
328
Industry P/E
Price to Book Value
1.47
EV to EBIT
-15.88
EV to EBITDA
-26.81
EV to Capital Employed
1.72
EV to Sales
3.56
PEG Ratio
3.18
Dividend Yield
NA
ROCE (Latest)
-10.81%
ROE (Latest)
0.45%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
NET SALES(Q)
At HKD 1,308.51 MM has Grown at 173.06%
ROCE(HY)
Highest at -1.15%
DEBTORS TURNOVER RATIO(HY)
Highest at 4.37 times
OPERATING PROFIT(Q)
Highest at HKD 25.61 MM
OPERATING PROFIT MARGIN(Q)
Highest at 1.96 %
PRE-TAX PROFIT(Q)
At HKD -28.18 MM has Grown at 89.64%
NET PROFIT(Q)
At HKD -60.41 MM has Grown at 77.79%
EPS(Q)
Highest at HKD -0.02
-7What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at -0.9 %
INTEREST(Q)
Highest at HKD 17.98 MM
Here's what is working for Everest Medicines Ltd.
Net Sales
At HKD 1,308.51 MM has Grown at 173.06%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (HKD MM)
Operating Profit
Highest at HKD 25.61 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (HKD MM)
Operating Profit Margin
Highest at 1.96 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
At HKD -28.18 MM has Grown at 89.64%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (HKD MM)
Net Profit
At HKD -60.41 MM has Grown at 77.79%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (HKD MM)
EPS
Highest at HKD -0.02
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (HKD)
Debtors Turnover Ratio
Highest at 4.37 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Depreciation
Highest at HKD 97.45 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (HKD MM)
Depreciation
At HKD 97.45 MM has Grown at 12.97%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (HKD MM)
Here's what is not working for Everest Medicines Ltd.
Interest
Highest at HKD 17.98 MM
in the last five periods and Increased by 39.29% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (HKD MM)
Debt-Equity Ratio
Highest at -0.9 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Non Operating Income
Highest at HKD 0.84 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
Footer loading
